PCSK9 and metabolic dysfunction-associated steatotic liver disease: Scicali et al. found that PCSK9-iTs significantly improved many biomarkers for steatosis in FH patients and achieved an elevated high-density lipoprotein (HDL)/TG ratio.195 Besides, the favorable impact of PCSK9-iTs on hepatic activities and functions in NAFLD patients was also observed in a retrospective clinical analysis.196 Further, Sekhon et al. reported that Evolocumab led to an over 80% reduction in liver transaminases in a NASH patient, and the subsequent liver biopsy revealed normalized histology.197